Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open‐label, active‐controlled study

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review5 ◽

2019 ◽

Author(s):

Christine Mermier

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review2 ◽

2019 ◽

Author(s):

Christine Mermier

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review3 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review2 ◽

2019 ◽

Author(s):

Zhengxiang Huang

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension

Diabetes Obesity and Metabolism ◽

10.1111/dom.12235 ◽

2013 ◽

Vol 16 (5) ◽

pp. 418-425 ◽

Cited By ~ 32

Author(s):

T. Kadowaki ◽

K. Kondo

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Diabetes Obesity and Metabolism ◽

10.1111/dom.13750 ◽

2019 ◽

Vol 21 (8) ◽

pp. 1990-1995 ◽

Cited By ~ 5

Author(s):

Masaya Koshizaka ◽

Ko Ishikawa ◽

Ryoichi Ishibashi ◽

Yoshiro Maezawa ◽

Kenichi Sakamoto ◽

...

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Randomized Controlled Study ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Randomized Controlled ◽

Fat Reduction

Anti-albuminuric effect of losartan versus amlodipine in hypertensive Japanese patients with type 2 diabetes mellitus: A prospective, open-label, randomized, comparative study

Current Therapeutic Research ◽

10.1016/j.curtheres.2007.04.002 ◽

2007 ◽

Vol 68 (2) ◽

pp. 94-106 ◽

Cited By ~ 2

Author(s):

Yasuhiro Ohno ◽

Akiyoshi Nishimura ◽

Hiroshi Iwai ◽

Noriyuki Hirota ◽

Takaaki Yamauchi ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Comparative Study ◽

Japanese Patients ◽

Open Label

Decision letter for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review4 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽